Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Xunfei Healthcare Technology Co., Ltd.
訊飛醫療科技股份有限公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2506)

VOLUNTARY ANNOUNCEMENT
ENTERING INTO A MEMORANDUM OF UNDERSTANDING WITH PT DSST MAS GEMILANG

This announcement is voluntarily made by Xunfei Healthcare Technology Co., Ltd. (the "**Company**", together with its subsidiaries, the "**Group**") for the purpose of providing the shareholders of the Company ("**Shareholders**") and potential investors with information on the latest business development of the Group.

MEMORANDUM OF UNDERSTANDING

On June 9, 2026, the Company entered into a Memorandum of Understanding on Strategic Cooperation in the Field of Artificial Intelligence Medical Technology (the "**MOU**") with PT DSST Mas Gemilang (the "**Cooperating Party**"). Pursuant to the MOU, the parties intend to establish a long-term strategic cooperation, combining the Company's artificial intelligence medical technology with the Cooperating Party's digital infrastructure, investment capabilities and local market resources in Indonesia, to jointly achieve the following goals: (a) accelerating the deployment of AI solutions within Indonesia's healthcare system; (b) supporting the priority public health programs of the Government of the Republic of Indonesia; and (c) exploring opportunities for co-investment, joint product development, and commercialization across Indonesia's and Southeast Asia's digital health sector.

REASONS FOR AND BENEFITS OF ENTERING INTO THE MOU

The Company is a leader in China's artificial intelligence healthcare sector, and is committed to becoming an artificial intelligence-powered medical assistant for every doctor and an artificial intelligence-powered health partner for everyone. Leveraging medical large model technology and the construction of a medical knowledge base, the Company consistently maintains its leading position in medical large models. The Company has

created the artificial intelligence-powered Intelligent Assistant product series and the artificial intelligence-powered Health Partner product series to empower governments, hospitals and patients.

The Cooperating Party is an investment holding platform incorporated in Indonesia focusing on the digital infrastructure and technology sectors. It is a member of Sinar Mas, and its parent company is PT Dian Swastatika Sentosa Tbk (IDX: DSSA), a company listed on the Indonesia Stock Exchange. Based on the Cooperating Party's public information, the Cooperating Party manages a diversified investment portfolio covering businesses such as data centers, information technology solutions and e-wallets, and is committed to building digital infrastructure for the Indonesian economy.

The Board is of the view that entering into the MOU is in the interests of the Company and its Shareholders as a whole. Southeast Asia is one of the fastest-growing regions in terms of digital healthcare demand worldwide. The Company can leverage its world-class AI medical technology, combined with the Cooperating Party's investment capabilities and local market channels, to accelerate its entry into Indonesia, its first key overseas market, in a localized and compliant manner. This will also lay the foundation for subsequent joint investment, joint product development and commercialization, thereby further advancing the Company's internationalization strategy.

GENERAL INFORMATION

The Board wishes to emphasize that the cooperation contemplated under the MOU may or may not proceed, and as at the date of this announcement, the parties have not entered into any legally binding agreement in respect of any specific transaction contemplated under the MOU. Should the transactions contemplated under the MOU materialize, the Company will make further announcement(s) in due course in accordance with the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and other applicable laws and regulations.

By order of the Board
Xunfei Healthcare Technology Co., Ltd.
Dr. Tao Xiaodong
Executive Director

Hong Kong, June 17, 2026

As at the date of this announcement, the Board of the Company comprises: (i) Dr. Tao Xiaodong as executive director; (ii) Dr. Liu Qingfeng, Mr. Zhao Zhiwei and Mr. Duan Dawei as non-executive directors; and (iii) Prof. Wang Yang, Prof. Zhao Huifang and Mr. Tan Ching as independent non-executive directors.